Tumor Lysate, Particle Only (TLPO) Vaccine

Cancer tumor cells have a particular molecular profile that represents the antigenic load of a patient’s individual disease.  In a patient with clinical cancer, tumor cells die naturally and the patient’s immune system sees those antigens and tolerates the differences from a normal cell.  In order for the immune system to mount a meaningful immune response, it must see the differences like it would see a pathogenic foreign invader. The Elios approach accommodates this requirement by presenting the entire repertoire of a patients antigen profile (known antigens, unknown antigens, neo-antigens, etc) to the patient’s immune system in ann inflammatory environment.  The type of environment that the immune system typically sees pathogenic challenges.

Elios’ novel approach takes a small amount of a patient’s tumor, which can be collected at definitive surgery or through biopsy.  The tumor cells are loaded into a proprietary particle delivery system and the particle is coated with a proprietary immunostimulant that holds the lysate payload inside the particle and creates a massive monocytic event at the site of the intra-dermal injection.